Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Claudin18.2 Targeted Activated Dendritic Cells
- Development stage
- Phase 1
- Lead developer
- Hainan Cancer Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
Claudin18.2 Targeted Activated Dendritic Cells is an autologous cell therapy consisting of dendritic cells (DCs) genetically modified to express a Claudin 18.2 (CLDN18.2) chimeric antigen receptor (CAR) and an activation domain. Developed by Hainan Cancer Hospital, this therapy is designed to treat advanced pancreatic cancer. The mechanism involves activating the DCs to precisely target tumor sites, reshaping the tumor immune microenvironment, and breaking down immunosuppressive barriers. In clinical settings, it is often evaluated in combination with Claudin18.2-targeted CAR-T cells to enhance the penetration and persistence of the T cells within the tumor by modifying the local immune landscape.
- Other names
- Claudin18.2 Targeted Activated DCClaudin-18.2 Targeted Activated DCClaudin 18.2 Targeted Activated DCClaudin18.2-Targeted Activated Dendritic CellsClaudin-18.2-Targeted Activated Dendritic CellsClaudin 18.2-Targeted Activated Dendritic Cells
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on Claudin18.2 Targeted Activated Dendritic Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Claudin18.2 Targeted Activated Dendritic Cells.